Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.
- 18 April 1998
- Vol. 316 (7139) , 1241-2
Abstract
No abstract availableThis publication has 0 references indexed in Scilit:
This publication has 0 references indexed in Scilit: